IBT is developing multivalent vaccines against S. aureus toxins. The goal of the program is to develop practical vaccine candidates to prevent morbidity from S. aureus infections and its complications.
IBT has developed a set of rationally designed S. aureus toxoids which induce protective immune responses against a number of S. aureus toxins including hemolysins, bicomponent pore-forming toxins, and superantigens.
IBT’s in vitro and in vivo data show significant protection against S. aureus disease models. The next step in the program is to conduct further characterization and evaluation of the candidates, optimize the set of candidates into a series of one or more multivalent leads, and proceed towards proof of concept and IND-directed studies.